Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
SAN DIEGO–(BUSINESS WIRE)–Iambic Therapeutics today announced it will highlight new preclinical data for IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego.
The poster presentation will showcase preclinical data illustrating how the unique binding mechanism and potent HER2 activity of IAM1363 overcomes multiple resistance mechanisms and how its strong EGFR avoidance widens the safety margin. IAM1363 potently inhibits both the wild type and mutant forms of HER2, showing over 1000-fold selectivity against EGFR due to a unique binding mode and tumor enhancement not seen with other HER2 inhibitors, leading to exceptional in vivo efficacy and tolerability in various HER2-driven cancer models, including those resistant to existing HER2-targeting agents. IAM1363 is now in a Phase 1 clinical study.
Poster Presentation Details:
Presentation Title: Validation of a novel Type II HER2 inhibitor through preclinical studies across various cancer models
Abstract Number: 1980/29
Session Title: Kinase and Phosphatase Inhibitors 2
Location: Poster Section 25
Date and Time: Monday, April 8th; 9:00 – 12:30 PT
Presenter: Lana Kulyk, PhD
About Iambic Therapeutics
Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
Contacts
Jason Glashow
Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai